Publicaciones en colaboración con investigadores/as de University Medical Center Freiburg (34)

2024

  1. Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells

    Science Immunology, Vol. 9, Núm. 91

2023

  1. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    The European respiratory journal, Vol. 62, Núm. 4

  2. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 64, Núm. 4

  3. Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus: a prospective observational multicentre cohort

    Clinical Microbiology and Infection, Vol. 29, Núm. 4, pp. 498-505

  4. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

  5. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

2022

  1. A Novel GATA1 Variant in the C-Terminal Zinc Finger Compared with the Platelet Phenotype of Patients with A Likely Pathogenic Variant in the N-Terminal Zinc Finger

    Cells, Vol. 11, Núm. 20

  2. MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S303-S304

  3. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884

2021

  1. 2021 European myeloma network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde

    Haematologica, Vol. 106, Núm. 11, pp. 2799-2812

  2. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  5. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

    The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204

  6. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

  7. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study

    The Lancet Infectious Diseases, Vol. 20, Núm. 12, pp. 1409-1417

2018

  1. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

  2. Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients

    PLoS ONE, Vol. 13, Núm. 12

2017

  1. A case of mosaicism in ectodermal dysplasia–skin fragility syndrome

    British Journal of Dermatology